Valeant has overcome manufacturing problems at a Bausch & Lomb plant to win approval of its long-delayed eye drug.
CDMO Almac has added to its analytical services with the acquisition of a privately held drug testing and analytical services company.
The FDA has banned the OTC products of a Canadian drugmaker after finding it was using ingredients from a supplier already on its import alert list.
Manufacturing issues at legacy Hospira plants have taken a toll on Pfizer’s earnings and created serious problems for some of its clients.
Biocon has seen its earnings hit by FDA and EU regulatory issues at its Indian plant that makes the biosimilars it and partner Mylan have developed.
Merck KGaA and South Korea’s Samsung BioLogics are deepening a collaboration even as Samsung reported an operating profit for the first time.
Shire intends to take some manufacturing of its rare disease drug Cinryze in house after problems with a contractor led to a shortage of the drug.
Sanofi is spending billions of dollars on modern plants that use robotics and analytics to improve manufacturing efficiencies.
Regeneron is expanding its biologics plant in Ireland, investing another $100 million and adding another 300 jobs
India-based API maker Vital Laboratories was slapped with a warning letter from the FDA over manufacturing and records issues at its Plant II located in Vapi,…